# AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

Source: https://onco.cc/trials/nct06137118/  
OnCo record `nct06137118` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Surovatamig in acute lymphoblastic leukaemia, run by AstraZeneca, now recruiting.

## Summary

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia is a phase 1/2 interventional study registered as NCT06137118 by AstraZeneca, with 255 participants planned, started 2023-12-29 and due to reach its primary completion in 2028-02-11. Interventions recorded: Surovatamig.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06137118
- Phase: 1/2
- Setting: A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia
- Sponsor: AstraZeneca
- Enrolled: 255

## Sources

- ClinicalTrials.gov NCT06137118: https://clinicaltrials.gov/study/NCT06137118

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct06137118.json